Scarica l'app Stockscreener
2.63
1.50%
-0.04
Pre-mercato:
2.74
0.11
+4.18%
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Fibonacci Time Zone - newsline.com
TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressHealthcare Earnings Report - newsline.com
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - TipRanks
Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan
Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan
Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan
Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com
This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating - Investing.com
HC Wainwright Initiates Tvardi Therapeutics at Buy With $9 Price Target - Moomoo
H.C. Wainwright Initiates Tvardi Therapeutics(TVRD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Tvardi Therapeutics: STAT3 inhibitor TTI-109 aims to address fibrosis and immune disorders, with key data expected soon - TradingView
Tvardi Therapeutics: STAT3 inhibitor programs advance with new data expected, targeting fibrosis and immune disorders - TradingView
MSN Money - MSN
TVRD Q1 2026 Earnings: Net Loss Narrows as Clinical Pipeline AdvancesEarnings Beat Streak - newsline.com
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Tvardi Therapeutics (TVRD) Declines 4%: Support at $3.18 in FocusVWAP Deviation - newsline.com
Tvardi Therapeutics (TVRD) Holds Steady Near Support Amid Low-Volume TradingShort Setup Alerts - The Legal Advocate
Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser
Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewswire
Tvardi Therapeutics (TVRD) Trading at $4.00 — Key Decision Point 2026-05-18Institutional Volume - The Legal Advocate
What Tvardi Therapeutics (TVRD)'s +1.01% Jump Means for Investors 2026-05-17Market Neutral Pair - Newser
[EFFECT] Tvardi Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD) - The Globe and Mail
Barclays Maintains Tvardi Therapeutics(TVRD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Number of shareholders of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
593,758 resale shares by Tvardi Therapeutics (NASDAQ: TVRD) post‑merger - Stock Titan
Tvardi Therapeutics 4Q Research and Development Expenses $4.9M >TVRD - Moomoo
Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Tvardi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tvardi Therapeutics 1Q 2026: Revenue ($6.81M), Net income ($6.8M), EPS ($0.73) — 10-Q Summary - TradingView
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Net loss narrowed to $6.8M, but continued operations depend on securing additional funding - TradingView
Tvardi Therapeutics: Net loss narrowed in Q1 2026 as clinical milestones for TTI-109 and TTI-101 approach - TradingView
Tvardi: Q1 Earnings Snapshot - marketscreener.com
Tvardi Therapeutics (NASDAQ: TVRD) posts Q1 2026 loss and warns on going concern - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) narrows Q1 loss and targets 2026 STAT3 trial readouts - Stock Titan
Two biotech readouts ahead as Tvardi says cash lasts into Q4 - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):